Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company''s flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump''s software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. Its products in development include t:sport insulin delivery system; and connected (mobile) health offerings. Tandem Diabetes Care, Inc. has a development and commercialization agreement with Dexcom, Inc. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. Lloyds forecast: will Lloyds share price return to £1? Third party data forecastWhat’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
13:36, 8 July 2024
Infosys shareholders: Who owns the most INFY stock?Who are the major shareholders and decision-makers of Infosys?
07:12, 29 April 2024
Tesla shareholders: Who owns the most TSLA stock?In this guide to Tesla’s ownership structure, we look at the biggest TSLA shareholders – both institutional and individual
08:00, 19 April 2024
US Earnings Week Ahead: Walt Disney, Uber, and Pepsi CoThe last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.
14:43, 2 February 2024